

Kevin A Schulman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6667016/publications.pdf>

Version: 2024-02-01

147
papers

6,613
citations

76196

40
h-index

76769

74
g-index

156
all docs

156
docs citations

156
times ranked

7685
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring Workplace Testing with Real-Time Polymerase Chain Reaction SARS-CoV-2 Testing. Journal of the American Board of Family Medicine, 2022, 35, 96-101.	0.8	2
2	Digital Health COVID-19 Impact Assessment: Lessons Learned and Compelling Needs. NAM Perspectives, 2022, 2022, .	1.3	22
3	The Dysfunctional Health Benefits Market and Implications for US Employers and Employees. JAMA - Journal of the American Medical Association, 2022, 327, 323.	3.8	1
4	Identifying solutions to meet unmet needs of family caregivers using human-centered design. BMC Geriatrics, 2022, 22, 94.	1.1	4
5	Building a Learning Health System: Creating an Analytical Workflow for Evidence Generation to Inform Institutional Clinical Care Guidelines. Applied Clinical Informatics, 2022, 13, 315-321.	0.8	4
6	Association between state-level malpractice environment and clinician electronic health record (EHR) time. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 1069-1077.	2.2	4
7	Racial disparities in healthcare and health. Health Services Research, 2022, 57, 218-222.	1.0	10
8	Trends and determinants of retail prescription drug costs. Health Services Research, 2022, 57, 548-556.	1.0	5
9	Detailed characterization of hospitalized patients infected with the Omicron variant of SARS-CoV-2. Journal of Internal Medicine, 2022, 292, 385-387.	2.7	3
10	Price and Quality in the Generic Pharmaceutical Market. Circulation, 2022, 145, 1185-1187.	1.6	2
11	Assessment of Electronic Health Record Use Between US and Non-US Health Systems. JAMA Internal Medicine, 2021, 181, 251.	2.6	64
12	Beyond Politics – Promoting Covid-19 Vaccination in the United States. New England Journal of Medicine, 2021, 384, e23.	13.9	133
13	Ethical issues in using ambient intelligence in health-care settings. The Lancet Digital Health, 2021, 3, e115-e123.	5.9	48
14	Reducing administrative costs in US health care: Assessing single payer and its alternatives. Health Services Research, 2021, 56, 615-625.	1.0	6
15	The COVID-19 Pandemic – An Opportune Time to Update Medical Licensing. JAMA Internal Medicine, 2021, 181, 307.	2.6	26
16	When Vaccine Apathy, Not Hesitancy, Drives Vaccine Disinterest. JAMA - Journal of the American Medical Association, 2021, 325, 2435.	3.8	40
17	Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?. JAMA - Journal of the American Medical Association, 2021, 326, 383.	3.8	14
18	Early Convalescent Plasma for High-Risk Outpatients with Covid-19. New England Journal of Medicine, 2021, 385, 1951-1960.	13.9	177

#	ARTICLE	IF	CITATIONS
19	The No Surprises Act and Informed Financial Consent. <i>New England Journal of Medicine</i> , 2021, 385, 1348-1351.	13.9	12
20	Quantifying Parkinson's disease motor severity under uncertainty using MDS-UPDRS videos. <i>Medical Image Analysis</i> , 2021, 73, 102179.	7.0	37
21	Novel strategies to support global promotion of COVID-19 vaccination. <i>BMJ Global Health</i> , 2021, 6, e006066.	2.0	8
22	New Medicare Technology Add-On Payment Could Be Used As A Market Support Mechanism To Accelerate Antibiotic Innovation. <i>Health Affairs</i> , 2021, 40, 1926-1934.	2.5	1
23	Comanagement by Hospitalists: Why It Makes Clinical and Fiscal Sense. <i>American Journal of Medicine</i> , 2020, 133, 257-258.	0.6	6
24	Exploring payments in the US pharmaceutical market from 2011 to 2019: Update on pharmacy benefit manager impact. <i>American Heart Journal</i> , 2020, 227, 107-110.	1.2	3
25	Challenges In Ensuring The Quality Of Generic Medicines. <i>Health Affairs</i> , 2020, 39, 1643-1646.	2.5	3
26	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. <i>Diabetes Care</i> , 2020, 43, 2485-2492.	4.3	3
27	The unintended consequences of the 340B safety-net drug discount program. <i>Health Services Research</i> , 2020, 55, 153-156.	1.0	6
28	Are U.S. Hospitals Still "Recession-proof"? <i>New England Journal of Medicine</i> , 2020, 383, e82.	13.9	11
29	Examining Pharmaceutical Benefits in the United States: A Framework. <i>JAMA Health Forum</i> , 2020, 1, e200291.	1.0	3
30	Workforce Cost Model for Expanding Congenital and Rheumatic Heart Disease Services in Kenya. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2019, 10, 321-327.	0.3	3
31	The Implications of "Medicare for All" for US Hospitals. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1661.	3.8	19
32	Evaluating the quality of antihypertensive drugs in Lagos State, Nigeria. <i>PLoS ONE</i> , 2019, 14, e0211567.	1.1	7
33	Administrative Costs Associated With Physician Billing and Insurance-Related Activities at an Academic Health Care System. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 691.	3.8	91
34	The Evolving Pharmaceutical Benefits Market. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2269.	3.8	14
35	Understanding Frequent Emergency Department Use Among Primary Care Patients. <i>Population Health Management</i> , 2018, 21, 24-31.	0.8	31
36	The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: A policy primer for clinicians. <i>American Heart Journal</i> , 2018, 206, 113-122.	1.2	23

#	ARTICLE	IF	CITATIONS
37	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. <i>Gates Open Research</i> , 2018, 2, 23.	2.0	20
38	Financing and Distribution of Pharmaceuticals in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 21.	3.8	24
39	The economics of PCSK-9 inhibitors. <i>American Heart Journal</i> , 2017, 189, 200-201.	1.2	8
40	PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 711.	3.8	11
41	Modeling the Potential Economic Impact of the Medicare Comprehensive Care for Joint Replacement Episode-Based Payment Model. <i>Journal of Arthroplasty</i> , 2017, 32, 3268-3273.e4.	1.5	18
42	Barriers to Achieving Economies of Scale in Analysis of EHR Data. <i>Applied Clinical Informatics</i> , 2017, 08, 826-831.	0.8	36
43	Trends in hospital-physician integration in medical oncology. <i>American Journal of Managed Care</i> , 2017, 23, 624-627.	0.8	3
44	Patient Preferences for Features of Health Care Delivery Systems: A Discrete Choice Experiment. <i>Health Services Research</i> , 2016, 51, 704-727.	1.0	29
45	Reassessing ACOs and Health Care Reform. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 707.	3.8	17
46	Extreme Home Makeover â€” The Role of Intensive Home Health Care. <i>New England Journal of Medicine</i> , 2016, 375, 1707-1709.	13.9	18
47	Health Care Tax Inversions â€” Robbing Both Peter and Paul. <i>New England Journal of Medicine</i> , 2016, 374, 1005-1007.	13.9	6
48	Options to Promote Competitive Generics Markets in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2129.	3.8	18
49	Specialty Pharmaceuticals for Hyperlipidemia â€” Impact on Insurance Premiums. <i>New England Journal of Medicine</i> , 2015, 373, 1591-1593.	13.9	26
50	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. <i>American Heart Journal</i> , 2015, 170, 951-960.	1.2	7
51	Can Team-Based Care Improve Patient Satisfaction? A Systematic Review of Randomized Controlled Trials. <i>PLoS ONE</i> , 2014, 9, e100603.	1.1	63
52	The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care Costs. <i>Health Affairs</i> , 2014, 33, 1714-1720.	2.5	49
53	Shifting toward Defined Contributions â€” Predicting the Effects. <i>New England Journal of Medicine</i> , 2014, 370, 2462-2465.	13.9	1
54	The Partners HealthCare Settlement and the Future of Health Care Organizations. <i>Economists' Voice</i> , 2014, 11, .	0.2	0

#	ARTICLE	IF	CITATIONS
55	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. <i>JACC: Heart Failure</i> , 2014, 2, 159-165.	1.9	91
56	Health City Cayman Islands and the globalization of health services delivery. <i>American Heart Journal</i> , 2014, 167, 770-774.	1.2	3
57	Associations Between Seattle Heart Failure Model Scores and Medical Resource Use and Costs: Findings From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2014, 20, 541-547.	0.7	5
58	Associations Between Seattle Heart Failure Model Scores and Health Utilities: Findings From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2013, 19, 311-316.	0.7	15
59	Medical Resource Use, Costs, and Quality of Life in Patients With Acute Decompensated Heart Failure: Findings From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2013, 19, 611-620.	0.7	12
60	Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 113-119.	0.9	17
61	Cost-Effectiveness of Truncated Therapy for Hepatitis C Based on Rapid Virologic Response. <i>Value in Health</i> , 2012, 15, 876-886.	0.1	5
62	A model for the adoption of ICT by health workers in Africa. <i>International Journal of Medical Informatics</i> , 2012, 81, 773-781.	1.6	58
63	End Point Selection in Acute Decompensated Heart Failure Clinical Trials: Economic End Points. <i>Heart Failure Clinics</i> , 2011, 7, 529-537.	1.0	0
64	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology</i> , 2011, 12, 933-980.	5.1	571
65	Petryna, Adriana. 2009. When experiments travel: Clinical trials and the global search for human subjects. <i>Journal of Bioethical Inquiry</i> , 2011, 8, 95-96.	0.9	0
66	A policy approach to the development of molecular diagnostic tests. <i>Nature Biotechnology</i> , 2010, 28, 1157-1159.	9.4	15
67	Economic Evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of) Tj ETQq1 1 0.784314 rgBT /Overl 2010, 3, 374-381.	0.9	46
68	Economic Content in Medical Journal Advertisements for Medical Devices and Prescription Drugs. <i>Pharmacoeconomics</i> , 2010, 28, 429-438.	1.7	4
69	Personalized medicine and disruptive innovation: Implications for technology assessment. <i>Genetics in Medicine</i> , 2009, 11, 577-581.	1.1	23
70	Response to Letter Regarding Article, "Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial" • <i>Circulation</i> , 2009, 120, .	1.6	0
71	Decision making and quality of life in the treatment of cancer: a review. <i>Supportive Care in Cancer</i> , 2009, 17, 117-127.	1.0	92
72	Ethical and Scientific Implications of the Globalization of Clinical Research. <i>New England Journal of Medicine</i> , 2009, 360, 816-823.	13.9	628

#	ARTICLE	IF	CITATIONS
73	Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices. <i>Journal of General Internal Medicine</i> , 2008, 23, 50-56.	1.3	20
74	Does Reimportation Reduce Price Differences for Prescription Drugs? Lessons from the European Union. <i>Health Services Research</i> , 2008, 43, 1308-1324.	1.0	25
75	Cost-effectiveness of the oral adsorbent AST-20 versus placebo for chronic kidney disease. <i>Nephrology</i> , 2008, 13, 419-427.	0.7	6
76	Considerations of net present value in policy making regarding diagnostic and therapeutic technologies. <i>American Heart Journal</i> , 2008, 156, 879-885.	1.2	15
77	Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-?? Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. <i>Pharmacoeconomics</i> , 2008, 26, 435-446.	1.7	38
78	Fueling Innovation In Medical Devices (And Beyond): Venture Capital In Health Care. <i>Health Affairs</i> , 2008, 27, w68-w75.	2.5	28
79	Association Between the Medicare Modernization Act of 2003 and Patient Wait Times and Travel Distance for Chemotherapy. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 189.	3.8	44
80	Consistency of Financial Interest Disclosures in the Biomedical Literature: The Case of Coronary Stents. <i>PLoS ONE</i> , 2008, 3, e2128.	1.1	50
81	Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 480.	3.8	148
82	Is There a Price to Pay for Short-Term Savings in the Clinical Development of New Pharmaceutical Products?. <i>Drug Information Journal</i> , 2007, 41, 491-499.	0.5	1
83	Publication or presentation of results from multicenter clinical trials: Evidence from an academic medical center. <i>American Heart Journal</i> , 2007, 153, 674-680.	1.2	18
84	The medicare modernization act and reimbursement for outpatient chemotherapy. <i>Cancer</i> , 2007, 110, 2304-2312.	2.0	14
85	Entry and competition in generic biologics. <i>Managerial and Decision Economics</i> , 2007, 28, 439-451.	1.3	55
86	Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. <i>Supportive Care in Cancer</i> , 2007, 15, 869-876.	1.0	130
87	Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia. <i>Pharmacoeconomics</i> , 2006, 24, 479-494.	1.7	12
88	Analytic Considerations in Economic Evaluations of Multinational Cardiovascular Clinical Trials. <i>Value in Health</i> , 2006, 9, 281-291.	0.1	7
89	Trends in health care resource use for hepatitis C virus infection in the United States. <i>Hepatology</i> , 2005, 42, 1406-1413.	3.6	74
90	Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2366-2375.	6.7	9

#	ARTICLE	IF	CITATIONS
91	Perceived discrimination and reported delay of pharmacy prescriptions and medical tests. <i>Journal of General Internal Medicine</i> , 2005, 20, 578-583.	1.3	136
92	Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. <i>Current Medical Research and Opinion</i> , 2005, 21, 1527-1533.	0.9	13
93	Implications of Pharmacogenomics for Drug Development and Clinical Practice. <i>Archives of Internal Medicine</i> , 2005, 165, 2331.	4.3	61
94	Reducing the costs of phase III cardiovascular clinical trials. <i>American Heart Journal</i> , 2005, 149, 482-488.	1.2	114
95	Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>American Heart Journal</i> , 2005, 150, 323-329.	1.2	23
96	Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. <i>American Heart Journal</i> , 2005, 149, 434-443.	1.2	82
97	An Exploration of Relative Health Stock in Advanced Cancer Patients. <i>Medical Decision Making</i> , 2004, 24, 614-624.	1.2	22
98	Long-term survival estimates for imatinib versus interferon- γ plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2004, 101, 2584-2592.	2.0	35
99	Cost-effectiveness of imatinib versus interferon- γ plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2004, 101, 2574-2583.	2.0	72
100	The relationship between perceived barriers to healthcare and self-rated health. <i>Psychology, Health and Medicine</i> , 2004, 9, 476-482.	1.3	11
101	Commentary: Garson's "œphysicians, coverage, quality, and cost: the intertwined caduceus" <i>Journal of the American College of Cardiology</i> , 2004, 43, 6-7.	1.2	0
102	Differences in care-seeking behavior for acute chest pain in the United States and Japan. <i>American Heart Journal</i> , 2004, 147, 630-635.	1.2	12
103	Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). <i>American Heart Journal</i> , 2004, 148, 122-128.	1.2	44
104	Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone Lesions. <i>Medical Care</i> , 2004, 42, 164-175.	1.1	97
105	The Association of an Early Hemoglobin Response with Alternative Metrics to Evaluate Treatment Efficacy of Erythropoietic Agents. <i>Blood</i> , 2004, 104, 234-234.	0.6	1
106	Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. <i>Theoretical Medicine and Bioethics</i> , 2003, 24, 329-344.	0.4	64
107	Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care. <i>BMC Health Services Research</i> , 2003, 3, 1.	0.9	60
108	The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. <i>Cancer</i> , 2003, 98, 166-175.	2.0	101

#	ARTICLE	IF	CITATIONS
109	Improving patients' experiences with cancer treatment. <i>Clinical Therapeutics</i> , 2003, 25, 665-670.	1.1	1
110	Perceptions of Patients and Physicians Regarding Phase I Cancer Clinical Trials: Implications for Physician-Patient Communication. <i>Journal of Clinical Oncology</i> , 2003, 21, 2589-2596.	0.8	210
111	COMPARISON OF HOSPITAL COSTING METHODS IN AN ECONOMIC EVALUATION OF A MULTINATIONAL CLINICAL TRIAL. <i>International Journal of Technology Assessment in Health Care</i> , 2003, 19, 396-406.	0.2	27
112	Understanding Attitudes toward Clinical Research. <i>Journal of Ambulatory Care Management</i> , 2003, 26, 88-90.	0.5	2
113	A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors. <i>New England Journal of Medicine</i> , 2002, 347, 1335-1341.	13.9	190
114	Patient Choice of Breast Cancer Treatment. <i>Medical Care</i> , 2002, 40, 1068-1079.	1.1	37
115	Telemedicine: Future Promise for Dialysis Management. <i>Seminars in Dialysis</i> , 2002, 12, S-101-S-103.	0.7	1
116	A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. <i>Supportive Care in Cancer</i> , 2001, 9, 545-551.	1.0	71
117	A claims data approach to defining an episode of care. <i>Pharmacoepidemiology and Drug Safety</i> , 2001, 10, 417-427.	0.9	10
118	A comparison of scoring weights for the EuroQol _{v2} derived from patients and the general public. <i>Health Economics (United Kingdom)</i> , 2001, 10, 27-37.	0.8	48
119	Patterns of breast carcinoma treatment in older women. <i>Cancer</i> , 2000, 89, 561-573.	2.0	264
120	Medical errors: how the US Government is addressing the problem. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2000, 1, 35.	1.5	9
121	The Effect of Race on the Referral Process for Invasive Cardiac Procedures. <i>Medical Care Research and Review</i> , 2000, 57, 162-180.	1.0	77
122	Randomized Trial of Filgrastim, Sargramostim, or Sequential Sargramostim and Filgrastim After Myelosuppressive Chemotherapy for the Harvesting of Peripheral-Blood Stem Cells. <i>Journal of Clinical Oncology</i> , 2000, 18, 43-43.	0.8	92
123	Impact of Quality of Life on Patient Expectations Regarding Phase I Clinical Trials. <i>Journal of Clinical Oncology</i> , 2000, 18, 421-421.	0.8	115
124	Time to Presentation With Acute Myocardial Infarction in the Elderly. <i>Circulation</i> , 2000, 102, 1651-1656.	1.6	225
125	The Development of Standard Economic Datasets for use in the Economic Evaluation of Medicines. <i>Drug Information Journal</i> , 2000, 34, 1273-1291.	0.5	2
126	Patterns of breast carcinoma treatment in older women. <i>Cancer</i> , 2000, 89, 561-573.	2.0	9

#	ARTICLE	IF	CITATIONS
127	The timing of do-not-resuscitate orders and hospital costs. <i>Journal of General Internal Medicine</i> , 1999, 14, 190-192.	1.3	25
128	Regulating manufacturer-affiliated communication in the information age. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 593-597.	2.3	0
129	Treatment of hypertension in patients with comorbidities Results from the study of hypertensive prescribing practices (SHyPP). <i>American Journal of Hypertension</i> , 1999, 12, 333-340.	1.0	21
130	Item Responsiveness of a Rhinitis and Asthma Symptom Score During a Pollen Season. <i>Journal of Asthma</i> , 1999, 36, 459-465.	0.9	14
131	ACI-TIPI Clinical Trial. <i>Annals of Internal Medicine</i> , 1999, 131, 476.	2.0	0
132	Study of Hypertensive Prescribing Practices (SHyPP): A National Survey of Primary Care Physicians. <i>Journal of Clinical Hypertension</i> , 1999, 1, 106-114.	1.0	4
133	Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, 7, 481-493.		107
134	Resource costing for multinational neurologic clinical trials: methods and results. , 1998, 7, 629-638.		85
135	Treatment Choices by Seriously Ill Patients. <i>Medical Decision Making</i> , 1998, 18, 84-94.	1.2	24
136	Pharmacoeconomics: State of the Art in 1997. <i>Annual Review of Public Health</i> , 1997, 18, 529-548.	7.6	23
137	Confidence Intervals for Cost-Effectiveness Ratios: A Comparison of Four Methods. , 1997, 6, 243-252.		235
138	A Strategy for Collecting Pharmacoeconomic Data During Phase II/III Clinical Trials. <i>Pharmacoeconomics</i> , 1996, 9, 264-277.	1.7	49
139	Results of the Economic Evaluation of the FIRST Study: A Multinational Prospective Economic Evaluation. <i>International Journal of Technology Assessment in Health Care</i> , 1996, 12, 698-713.	0.2	47
140	The Effect of Pharmaceutical Benefits Managers: Is It Being Evaluated?. <i>Annals of Internal Medicine</i> , 1996, 124, 906.	2.0	42
141	Assessment of joint review of radiologic studies by a primary care physician and a radiologist. <i>Journal of General Internal Medicine</i> , 1996, 11, 608-612.	1.3	3
142	Evaluation of quality of life for diverse patient populations. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 87-104.	1.1	18
143	A Health Services Approach for the Evaluation of Innovative Pharmaceutical and Biotechnology Products. <i>Drug Information Journal</i> , 1995, 29, 1405-1414.	0.5	9
144	Relationships Between Sponsors and Investigators in Pharmacoeconomic and Clinical Research. <i>Pharmacoeconomics</i> , 1995, 7, 206-220.	1.7	29

#	ARTICLE	IF	CITATIONS
145	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. Gates Open Research, 0, 2, 23.	2.0	24
146	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. Gates Open Research, 0, 2, 23.	2.0	12
147	Pharmacoeconomics: Economic Evaluation of Pharmaceuticals. , 0, , 629-652.		0